Amoxicillin

Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin. Amoxicillin was granted FDA approval on 18 January 1974.

Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin. Amoxicillin was granted FDA approval on 18 January 1974.

Amoxicillin alone is indicated to treat susceptible bacterial infections of the ear, nose, throat, genitourinary tract, skin, skin structure, and lower respiratory tract. Amoxicillin is given with calvulanic acid to treat acute bacterial sinusitis, community acquired pneumonia, lower respiratory tract infections, acute bacterial otitis media, skin and skin structure infections, and urinary tract infections. Amoxicillin is given with omeprazole in the treatment of Helicobacter pylori (H. pylori) infection. Amoxicillin is used in combination with vonoprazan and clarithromycin as co-packaged triple therapy or in combination with vonoprazan as co-packaged dual therapy to treat H. pylori infection in adults.

• Acute Bacterial Sinusitis (ABS)
• Acute Otitis Media (AOM)
• Bacterial Infections
• Community Acquired Pneumonia (CAP)
• Duodenal ulcer caused by helicobacter pylori
• Genitourinary tract infection
• Helicobacter Pylori Infection
• Lower Respiratory Tract Infection (LRTI)
• Peptic Ulcer With H. Pylori Infection
• Sinusitis
• Skin and Subcutaneous Tissue Bacterial Infections
• Urinary Tract Infection
• Acute, uncomplicated Gonorrhea
• Ear, nose, and throat infections